Mga Batayang Estadistika
| CIK | 890465 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NPS Pharmaceuticals Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc 10-K/A - Annual Report - 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)* x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Commission File Number 0-23272 NPS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-0439579 (State or Other |
|
| February 23, 2015 |
BYLAWS NPS PHARMACEUTICALS, INC. * * * * * ARTICLE 1 OFFICES EX-3.2 3 a15-51111ex3d2.htm EX-3.2 Exhibit 3.2 BYLAWS OF NPS PHARMACEUTICALS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as t |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) NPS PHARMACEUTICALS, INC. (Name of Subject Company) NPS PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 62936P103 ( |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NPS PHARMACEUTICALS, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NPS PHARMACEUTICALS, INC. FIRST: The name of the corporation is NPS Pharmaceuticals, Inc. (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such addres |
|
| February 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2015 (February 20, 2015) NPS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 0-23272 87-0439579 (State or Other Jurisdiction of Inco |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
SHPG / Shire Plc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc POS AM - - POS AM As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc POSASR - - POSASR As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
NPSP / NPS Pharmaceuticals Inc POS AM - - POS AM As filed with the Securities and Exchange Commission on February 23, 2015 Registration No. |
|
| February 23, 2015 |
Shire Completes Acquisition of NPS Pharma Exhibit (a)(5)(xvi) Press Release www.shire.com Shire Completes Acquisition of NPS Pharma Dublin, Ireland – February 21, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and the subsequent acquisition of NPS Pharma. The tender offer expired at 12:00 midnight, New York City |
|
| February 17, 2015 |
NPSP / NPS Pharmaceuticals Inc / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NPS PHARMACEUTICALS INC (Name of Issuer) COM (Title of Class of Securities) 62936P103 (CUSIP Number) January 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 17, 2015 |
Exhibit (a)(5)(xiv) MEMO To: From: Cc: NPS Pharma Employees Carrie Frey, Shire Head of Corporate Planning and Program Management and Integration Lead Francois Nader, NPS Pharma President & CEO Susan Graf, NPS Pharma VP, Corporate Development and Strategy Date: February 16, 2015 Subject: Shire/NPS Pharma Integration Update Dear NPS Pharma Colleagues, When the Shire team first met with you last month following the initial merger announcement, we committed to communicating information to you when it became available. |
|
| February 17, 2015 |
Exhibit (a)(5)(xv) NPS Pharma Employee Proposed Acquisition Q&A 2/6/15 General 1. What will happen to NPS Pharma HQ in Bedminster? You announced that you are consolidating operations in Lexington, MA. Can you provide some perspective on Shire’s long range plan for facilities? We have not made any definitive decisions related to facilities at this time. 2. What do you plan to do with our internatio |
|
| February 17, 2015 |
NPSP / NPS Pharmaceuticals Inc / ING GROEP NV - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2014 (Date of Event Which Requ |
|
| February 17, 2015 |
SHPG / Shire Plc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0. |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) January 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2015 |
NPSP / NPS Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment npspharmaceuticals.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: NPS Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 62936P103 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropria |
|
| February 10, 2015 |
NPSP / NPS Pharmaceuticals Inc / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NPS PHARMACEUTICALS INC (Name of Issuer) COM (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 9, 2015 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit (a)(5)(xii) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NPS PHARMACEUTICALS STOCKHOLDERS ) CONSOLIDATED LITIGATION ) C. |
|
| February 9, 2015 |
SHPG / Shire Plc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0. |
|
| February 6, 2015 |
NPSP / NPS Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) NPS PHARMACEUTICALS, INC. (Name of Subject Company) NPS PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 62936P103 ( |
|
| January 29, 2015 |
NPSP / NPS Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) NPS PHARMACEUTICALS, INC. (Name of Subject Company) NPS PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 62936P103 ( |
|
| January 28, 2015 |
SHPG / Shire Plc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0. |
|
| January 28, 2015 |
NPSP / NPS Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) NPS PHARMACEUTICALS, INC. (Name of Subject Company) NPS PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 62936P103 ( |
|
| January 26, 2015 |
EFiled: Jan 23 2015 03:22PM EST Transaction ID 56655578 Case No. 10577-VCN Exhibit (a)(5)(xi) EFiled: Jan 23 2015 03:22PM EST Transaction ID 56655578 Case No. |
|
| January 26, 2015 |
NPSP / NPS Pharmaceuticals Inc SC 14D9/A - - SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) NPS PHARMACEUTICALS, INC. (Name of Subject Company) NPS PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 62936P103 ( |
|
| January 26, 2015 |
SHPG / Shire Plc. SC TO-T/A - - FORM SC TO-T/A SC TO-T/A 1 dp52803sctota.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing P |
|
| January 26, 2015 |
Exhibit (a)(5)(x) Press Release www.shire.com Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone) Dublin, Ireland – January 23, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) notes the announcement today by NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) that the U.S. Food and Drug Administration (FDA) has approved NATPARA® (parathyroid hormone) as an adjun |
|
| January 26, 2015 |
EFiled: Jan 26 2015 11:40AM EST Transaction ID 56661300 Case No. 10580-VCN Exhibit (a)(5)(xii) EFiled: Jan 26 2015 11:40AM EST Transaction ID 56661300 Case No. |
|
| January 23, 2015 |
SHPG / Shire Plc. SC TO-T - - SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 23, 2015 |
NPSP / NPS Pharmaceuticals Inc SC 14D9 - - SC 14D9 QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 23, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of NPS Pharmaceuticals, Inc. |
|
| January 23, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(i) Offer to Purchase for Cash Any and All Outstanding Shares of Common Stock of NPS Pharmaceuticals, Inc. |
|
| January 23, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(iv) Offer to Purchase for Cash Any and All Outstanding Shares of Common Stock of NPS Pharmaceuticals, Inc. |
|
| January 23, 2015 |
Exhibit (d)(2) EXECUTION COPY December 16, 2014 CONFIDENTIAL Shire Human Genetic Therapies, Inc. |
|
| January 23, 2015 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit (a)(5)(ix) EFiled: Jan 20 2015 04:14PM EST Transaction ID 56633135 Case No. |
|
| January 23, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(v) Offer to Purchase for Cash Any and All Outstanding Shares of Common Stock of NPS Pharmaceuticals, Inc. |
|
| January 23, 2015 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit (a)(5)(viii) EFiled: Jan 16 2015 04:42PM EST Transaction ID 56622127 Case No. |
|
| January 23, 2015 |
This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| January 23, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of NPS Pharmaceuticals, Inc. |
|
| January 20, 2015 |
NPSP / NPS Pharmaceuticals Inc CORRESP - - [Letterhead of Skadden, Arps, Slate, Meagher & Flom LLP] January 20, 2015 VIA EDGAR Tiffany Piland Posil Special Counsel Division of Corporation Finance Office of Mergers & Acquisitions Securities and Exchange Commission 100 F Street, N. |
|
| January 16, 2015 |
SHPG / Shire Plc. SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Tit |
|
| January 16, 2015 |
Shire and NPS Pharma Leadership in Rare Diseases GRAPHIC OMMITTED GRAPHIC OMMITTED GRAPHIC OMMITTED Exhibit 99.1 Shire and NPS Pharma Leadership in Rare Diseases GRAPHIC OMMITTED GRAPHIC OMMITTED GRAPHIC OMMITTED THIS COMMUNICATION IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL NPS PHARMA COMMON STOCK. THE OFFER TO BUY NPS PHARMA COMMON STOCK WILL ONLY BE MADE PURSUANT TO A TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCH |
|
| January 14, 2015 |
Exhibit 99.1 Continuing the Journey JP Morgan Healthcare Conference January 13, 2015 Flemming Ornskov, MD, MPH Chief Executive Officer [GRAPHIC OMITTED] "SAFE HARBOR" statement under the Private Securities Litigation Reform Act of 1995 and tender offer materials Statements included in this communication that are not historical facts are forward -looking statements. Such forward -looking statements |
|
| January 14, 2015 |
SHPG / Shire Plc. SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Tit |
|
| January 14, 2015 |
Shire plc JP Morgan Health Care Conference Transcript January 13, 2014 Shire plc JP Morgan Health Care Conference Transcript January 13, 2014 Presentation Speakers; Flemming Ornskov, Shire plc James Gordon, JPMorgan Q&A Participants James Gordon, JPMorgan Flemming Ornskov, Shire plc Phil Vickers, Shire plc Mark Enyedy, Shire plc Jeff Poulton, Shire plc Roger Adsett, Shire plc Unverified Participants Presentation James Gordon Good afternoon. |
|
| January 14, 2015 |
SHPG / Shire Plc. SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Tit |
|
| January 12, 2015 |
NPS PHARMACEUTICALS, INC. CHANGE IN CONTROL SEVERANCE PAY PLAN AS AMENDED THROUGH JANUARY 11, 2015 Exhibit 10.1 NPS PHARMACEUTICALS, INC. CHANGE IN CONTROL SEVERANCE PAY PLAN AS AMENDED THROUGH JANUARY 11, 2015 1. Introduction. The purpose of the NPS Pharmaceuticals, Inc. Change in Control Severance Pay Plan (the “Plan”) is to provide severance benefits to eligible employees of NPS Pharmaceuticals, Inc. and its subsidiaries (the “Company”) when there has been a “change in control” of the Compan |
|
| January 12, 2015 |
NPSP / NPS Pharmaceuticals Inc SC14D9C - - SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company) NPS PHARMACEUTICALS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 62936P103 (CUSIP Number of |
|
| January 12, 2015 |
Exhibit 99.2 Dear Colleagues, Today is a significant day in the history of NPS Pharma. A few moments ago we announced that we have entered into a merger agreement with Shire for $46 per share. This transaction of over $5 billion is a true testament to the value that each one of you has created through your outstanding contributions and steadfast commitment to NPS Pharma and the patients we serve. |
|
| January 12, 2015 |
Exhibit 10.1 EXECUTION VERSION SHIRE PLC as the Company CITIGROUP GLOBAL MARKETS LIMITED as mandated lead arranger and bookrunner with CITIBANK INTERNATIONAL LIMITED as Agent US$ 850,000,000 TERM FACILITY AGREEMENT DATED 11 JANUARY 2015 Slaughter and May One Bunhill Row London EC1Y 8YY (MJD) CONTENTS Clause Page 1. Definitions and interpretation 1 2. The Facility 22 3. Purpose 24 4. Conditions of |
|
| January 12, 2015 |
AMENDED AND RESTATED NPS PHARMACEUTICALS, INC. ADOPTED BY THE BOARD OF DIRECTORS JANUARY 11, 2015 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NPS PHARMACEUTICALS, INC. ADOPTED BY THE BOARD OF DIRECTORS ON JANUARY 11, 2015 TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 CORPORATE SEAL 1 Section 2.1 Corporate Seal 1 ARTICLE 3 STOCKHOLDERS’ MEETINGS 1 Section 3.1 Place of Meetings 1 Section 3.2 Annual Meeting 1 Section 3.3 Special Me |
|
| January 12, 2015 |
NPSP / NPS Pharmaceuticals Inc SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Tit |
|
| January 12, 2015 |
Exhibit 99.9 Town Hall January 12, 2015 2 Important Information for Investors and Security Holders The tender offer for the outstanding common stock of NPS Pharmaceuticals has not yet commenced. This communication does not constitute an offer to buy or a solicitation of an offer to sell any securities. On the commencement date of the tender offer, a tender offer statement on Schedule TO, including |
|
| January 12, 2015 |
Exhibit 99.1 Press Release www.shire.com Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech Transaction valued at $5.2 billion Enhances growth profile Dublin, Ireland and Bedminster, NJ – January 11, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that the companies have entered into a merger agreement pursuant to which |
|
| January 12, 2015 |
Exhibit 99.3 Employee FAQ 1: What was announced? Shire and NPS Pharma have entered into a merger agreement under which Shire will acquire NPS Pharma for $46 per share in an all cash transaction worth more than $5 billion. This offer represents a 51% premium to our unaffected share price of $30.47 on December 16, 2014 the day before rumors regarding a potential transaction were reported in the medi |
|
| January 12, 2015 |
Exhibit 99.6 January 11, 2015 Dear Patient Advocate: I am writing to inform you that NPS Pharma has entered into an agreement to be acquired by Shire. We believe this transaction will help accelerate NPS Pharma’s vision of creating a world where every person living with a rare disease has a therapy. Importantly, Shire shares our commitment to patients and passion for developing effective treatment |
|
| January 12, 2015 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of JANUARY 11, 2015 among NPS PHARMACEUTICALS, INC., SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, KNIGHT NEWCO 2, INC. and SHIRE PLC (solely for the purposes set forth in Section 12.14) TABLE OF CONTENTS PAGE ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 9 ARTICL |
|
| January 12, 2015 |
Exhibit 99.8 Shire to Acquire NPS Pharma Conference call Transcript Date: January 11, 2015 Time: 6:00 p.m. GMT/1:00 .pm. EST/10:00 a.m. PST Speakers: Flemming Ornskov, MD, MPH CEO, Shire plc Francois Nader, MD, MBA CEO, NPS Pharmaceuticals, Inc. Company Participants · Flemming Ornskov, Shire · Francois Nader, NPS Pharma · Jeff Poulton, Shire · Philip Vickers, Shire · Roger Adsett, Shire · Mark Eny |
|
| January 12, 2015 |
EX-2.1 2 dp52541ex0201.htm EXHIBIT 2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of JANUARY 11, 2015 among NPS PHARMACEUTICALS, INC., SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, KNIGHT NEWCO 2, INC. and SHIRE PLC (solely for the purposes set forth in Section 12.14) TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitiona |
|
| January 12, 2015 |
SHPG / Shire Plc. SC TO-C - - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 (January 11, 2015) SHIRE PLC (Exact name of registrant as specified in its charter) Jersey, Channel Islands 0-29630 98-0601486 (State or other jurisdiction of incorpo |
|
| January 12, 2015 |
NPSP / NPS Pharmaceuticals Inc SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Tit |
|
| January 12, 2015 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of JANUARY 11, 2015 among NPS PHARMACEUTICALS, INC., SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED, KNIGHT NEWCO 2, INC. and SHIRE PLC (solely for the purposes set forth in Section 12.14) TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 9 ARTIC |
|
| January 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2015 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission |
|
| January 12, 2015 |
Exhibit 99.5 January 11, 2015 Dear Investigator: We would like to inform you that NPS Pharma has entered into an agreement to be acquired by Shire. We believe this transaction will strengthen our effort to develop and deliver meaningful treatments to patients with rare diseases globally. As you may know, Shire is a global biopharmaceutical company that strives to enable people with life-altering c |
|
| January 12, 2015 |
Exhibit 99.4 January 11, 2015 Dear Valued [Partner / Supplier]: I am writing to inform you that NPS Pharma has entered into an agreement to be acquired by Shire. We believe this transaction will help accelerate NPS Pharma’s vision of creating a world where every person living with a rare disease has a therapy. We expect to complete the transaction in the first quarter of 2015 following customary c |
|
| January 12, 2015 |
Exhibit 10.1 EXECUTION VERSION SHIRE PLC as the Company CITIGROUP GLOBAL MARKETS LIMITED as mandated lead arranger and bookrunner with CITIBANK INTERNATIONAL LIMITED as Agent US$ 850,000,000 TERM FACILITY AGREEMENT DATED 11 JANUARY 2015 Slaughter and May One Bunhill Row London EC1Y 8YY (MJD) CONTENTS Clause Page 1. Definitions and interpretation 1 2. The Facility 22 3. Purpose 24 4. Conditions of |
|
| January 12, 2015 |
Exhibit 99.1 Press Release www.shire.com Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech Transaction valued at $5.2 billion Enhances growth profile Dublin, Ireland and Bedminster, NJ January 11, 2015 Shire plc (LSE: SHP, NASDAQ: SHPG) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that the companies have entered into a merger agreement pursuant to which |
|
| January 12, 2015 |
Exhibit 99.1 Press Release www.shire.com Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech Transaction valued at $5.2 billion Enhances growth profile Dublin, Ireland and Bedminster, NJ – January 11, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that the companies have entered into a merger agreement pursuant to which |
|
| January 12, 2015 |
NPSP / NPS Pharmaceuticals Inc SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 NPS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) KNIGHT NEWCO 2, INC. SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED SHIRE PLC (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Tit |
|
| January 12, 2015 |
NPSP / NPS Pharmaceuticals Inc SC TO-C - - FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 (January 11, 2015) SHIRE PLC (Exact name of registrant as specified in its charter) Jersey, Channel Islands 0-29630 98-0601486 (State or other jurisdiction of incorpo |
|
| January 12, 2015 |
Exhibit 99.7 Shire to acquire NPS Pharmaceuticals Further step in building a leading biotech Transaction valued at $5.2 billion Enhances growth profile January 11, 2015 Flemming Ornskov, MD, MPH CEO, Shire plc Francois Nader, MD, MBA CEO, NPS Pharmaceuticals, Inc. “SAFE HARBOR” statement under the Private Securities Litigation Reform Act of 1995 and tender offer materials Statements included in th |
|
| January 12, 2015 |
Exhibit 99.1 Press Release www.shire.com Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech Transaction valued at $5.2 billion Enhances growth profile Dublin, Ireland and Bedminster, NJ — January 11, 2015 — Shire plc (LSE: SHP, NASDAQ: SHPG) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that the companies have entered into a merger agreement pursuant to which |
|
| November 10, 2014 |
NPS Pharma Reports Third-Quarter 2014 Financial Results Exhibit 99.1 NPS Pharma Reports Third-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $28 million representing sequential growth of 28 percent Company on track to meet full-year financial guidance Commercial-readiness activities continue in advance of Natpara’s January 24 PDUFA date Conference call today at 4:30 PM ET BEDMINSTER, N.J.-(BUSINESS WIRE)-November 10, 2014-NPS Pha |
|
| November 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| November 5, 2014 |
NPSP / NPS Pharmaceuticals Inc CORRESP - - November 5, 2014 Letter November 5, 2014 VIA EDGAR Division of Corporation Finance U. |
|
| November 4, 2014 |
NPS Pharma Appoints Pierre Legault to Board of Directors Exhibit 99.1 NPS Pharma Appoints Pierre Legault to Board of Directors BEDMINSTER, N.J.-(BUSINESS WIRE)-November 4, 2014-NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors. Mr. Legault is chief |
|
| November 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission |
|
| September 12, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 12, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissi |
|
| September 12, 2014 |
FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism Exhibit 99.1 FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism NPS Pharma to host conference call today at 5:30 PM EDT PDUFA date for Natpara BLA is October 24, 2014 BEDMINSTER, N.J.-(BUSINESS WIRE)-September 12, 2014-NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the |
|
| August 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission F |
|
| August 6, 2014 |
NPS Pharma Reports Second-Quarter 2014 Financial Results Exhibit 99.1 NPS Pharma Reports Second-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $22 million representing sequential growth of 22 percent Full-year sales on track to meet guidance of $100 to $110 million Advisory Committee meeting to review Natpara® BLA on September 12; PDUFA date of October 24 Conference call today at 5:00 PM ET BEDMINSTER, N.J.-(BUSINESS WIRE)-August |
|
| June 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 10, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2014 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 19, 2014 |
NPSP / NPS Pharmaceuticals Inc / ING GROEP NV - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) May 9, 2014 (Date of Event Which Requires Filing of this Statem |
|
| May 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2014 |
As filed with the Securities and Exchange Commission on May 8, 2014 Registration No. |
|
| May 8, 2014 |
NPS Pharma Reports First-Quarter 2014 Financial Results Exhibit 99.1 NPS Pharma Reports First-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $18 million representing 17 percent sequential growth Full-year net sales guidance revised to $100 to $110 million from $110 to $120 million to reflect impact of delays in January and February sales Natpara® BLA review continues to progress with PDUFA date of October 24, 2014 Conference call |
|
| May 8, 2014 |
As filed with the Securities and Exchange Commission on May 8, 2014 Registration No. |
|
| May 7, 2014 |
Exhibit 10.3 NPS PHARMACEUTICALS, INC. 2014 OMNIBUS EQUITY COMPENSATION PLAN NONQUALIFIED STOCK OPTION SUMMARY OF AWARD NPS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2014 Omnibus Equity Compensation Plan (the “Plan”), hereby awards to the individual listed below (the “Participant”), a Nonqualified Stock Option to purchase shares of common stock of the Company ( |
|
| May 7, 2014 |
NPS PHARMACEUTICALS, INC. DEFERRED COMPENSATION PLAN Exhibit 10.5 NPS PHARMACEUTICALS, INC. DEFERRED COMPENSATION PLAN NPS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby establishes the NPS Pharmaceuticals, Inc., Deferred Compensation Plan (the “Plan”), effective June 1, 2014 (the “Effective Date”), for the purpose of attracting and retaining high quality executives and Directors, and promoting in them increased efficiency and |
|
| May 7, 2014 |
Exhibit 10.4 NPS PHARMACEUTICALS, INC. 2014 OMNIBUS EQUITY COMPENSATION PLAN RESTRICTED STOCK UNIT SUMMARY OF AWARD NPS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2014 Omnibus Equity Compensation Plan (the “Plan”), hereby awards to the individual listed below (the “Participant”), this Restricted Stock Unit Award representing the number of Restricted Stock Units |
|
| May 7, 2014 |
Exhibit 10.2 NPS PHARMACEUTICALS, INC. 2014 OMNIBUS EQUITY COMPENSATION PLAN INCENTIVE STOCK OPTION SUMMARY OF AWARD NPS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2014 Omnibus Equity Compensation Plan (the “Plan”), hereby awards to the individual listed below (the “Participant”), an Incentive Stock Option to purchase shares of common stock of the Company (“Comp |
|
| May 7, 2014 |
NPS PHARMACEUTICALS, INC. 2014 OMNIBUS EQUITY COMPENSATION PLAN EX-10.1 2 a14-118101ex10d1.htm EX-10.1 Exhibit 10.1 NPS PHARMACEUTICALS, INC. 2014 OMNIBUS EQUITY COMPENSATION PLAN NPS PHARMACEUTICALS, INC. 2014 OMNIBUS EQUITY COMPENSATION PLAN 1. Purpose NPS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby establishes the NPS Pharmaceuticals, Inc. 2014 Omnibus Equity Compensation Plan (the “Plan”), as set forth in this document. The Plan i |
|
| May 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission File |
|
| April 1, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2014 NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| February 18, 2014 |
Exhibit 99.1 NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014 – Gattex® delivers strong performance with 2013 sales of $31.8 million – – Global Short Bowel Syndrome franchise expected to grow by more than 250% in 2014 - – Natpara® BLA review underway with PDUFA date of October 24 – – Conference call today at 5:00 PM ET – BEDMINSTER, N.J |
|
| February 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 18, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 12, 2014 |
NPSP / NPS Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment npspharmaceuticals.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: NPS Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 62936P103 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropria |
|
| February 3, 2014 |
NPSP / NPS Pharmaceuticals Inc / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* NPS PHARMACEUTICALS, INC. (Name of Issuer) COMMON (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| January 8, 2014 |
NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook Exhibit 99.1 NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook — 2013 net Gattex® sales expected to be approximately $31.5 million — — Strong Gattex launch momentum as company ends 2013 with 303 patients on Gattex/Revestive and 530 prescriptions — BEDMINSTER, N.J.—(BUSINESS WIRE)—Jan. 8, 2014— NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company |
|
| January 8, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2014 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission |
|
| December 23, 2013 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 20, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| December 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 16, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| November 6, 2013 |
Exhibit 99.1 NPS Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Business Update - Full-year net sales guidance increased to $28 to $32 million with $16 million in net sales year to date - - Natpara BLA submitted for hypoparathyroidism; market research supports unmet medical need and significant long-term global sales potential - - Conference call today at 8:30 AM ET - BE |
|
| November 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission |
|
| October 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) September 30, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| August 8, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission F |
|
| August 8, 2013 |
NPS PHARMACEUTICALS, INC. THE BANK OF NEW YORK MELLON, as Trustee Dated as of August 8, 2013 Exhibit 4.2 NPS PHARMACEUTICALS, INC. and THE BANK OF NEW YORK MELLON, as Trustee Indenture Dated as of August 8, 2013 NPS PHARMACEUTICALS, INC. Reconciliation and Tie between Trust Indenture Act of 1939 and Indenture, dated as of August 8, 2013 Trust Indenture Act Section Indenture Sections §310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 §311(a) 613 (b |
|
| August 8, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on August 8, 2013 Registration No. |
|
| August 8, 2013 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) o THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju |
|
| August 8, 2013 |
Exhibit 99.1 NPS Pharmaceuticals Reports Second Quarter 2013 Financial Results and Provides Business Update - U.S. launch of Gattex® (teduglutide) accelerating with net product sales of $4.8 million in quarter - - $25 to $30 million in full-year net global Gattex® sales expected with 275 to 325 patients on therapy by year end - - Ex-U.S. markets expected to double global peak sales opportunity for |
|
| August 8, 2013 |
Statement Regarding Computation of Ratio of Earnings to Fixed Charges (in thousands) Exhibit 12.1 Statement Regarding Computation of Ratio of Earnings to Fixed Charges (in thousands) Year Ended December 31, Six Months Ended June 30, 2008 2009 2010 2011 2012 2013 Earnings (loss) Pre-tax loss $ (31,905 ) $ (19,606 ) $ (30,350 ) $ (36,249 ) $ (18,735 ) $ (20,181 ) Total fixed charges $ 65,534 $ 52,759 $ 45,365 $ 38,157 $ 18,721 $ 6,709 Total income (loss) before fixed charges $ 33,62 |
|
| June 21, 2013 |
Results of Operations and Financial Condition 8-K 1 a13-1543028k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 21, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of in |
|
| May 22, 2013 |
NPS Pharmaceuticals Prices Public Offering of Common Stock Exhibit 99.1 For Immediate Release Contact: Susan M. Mesco NPS Pharmaceuticals, Inc. (908) 450-5516 [email protected] NPS Pharmaceuticals Prices Public Offering of Common Stock BEDMINSTER, N.J.—(BUSINESS WIRE)—May 21, 2013—NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to t |
|
| May 22, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 22, 2013 |
6,000,000 Shares NPS Pharmaceuticals, Inc. Common Stock $14.53 per share Use these links to rapidly review the document Table of Contents Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| May 22, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 22, 2013 |
NPS PHARMACEUTICALS, INC. 6,000,000 Shares of Common Stock Underwriting Agreement Exhibit 1.1 EXECUTION COPY NPS PHARMACEUTICALS, INC. 6,000,000 Shares of Common Stock Underwriting Agreement May 21, 2013 J. P. MORGAN SECURITIES LLC MORGAN STANLEY & CO. LLC As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Ladies and Gentlemen: NPS Pharmaceutica |
|
| May 20, 2013 |
Use these links to rapidly review the document Table of Contents Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| May 9, 2013 |
Exhibit 10.1 2005 Omnibus Incentive Plan NPS Pharmaceuticals, Inc. As amended through May 7, 2013 (subject to stockholder approval) Article 1. Establishment, Purpose, and Duration 1.1 Establishment. NPS Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to as the “Company”), establishes an incentive compensation plan to be known as the NPS Pharmaceuticals, Inc. 2005 Omnibus Incent |
|
| May 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission File |
|
| May 9, 2013 |
S-8 1 a13-117891s8.htm S-8 As filed with the Securities and Exchange Commission on May 9, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NPS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 87-0439579 (State or other jurisdiction of incorporation |
|
| May 9, 2013 |
Exhibit 99.1 NPS Pharmaceuticals Reports First Quarter 2013 Financial Results - Gattex launch off to a strong start with 160 prescriptions received to date and 42 patients now on therapy - - Strategic progress highlighted by global expansion - - Conference call today at 8:30 AM ET - BEDMINSTER, N.J.-(BUSINESS WIRE)-May 9, 2013-NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company p |
|
| May 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission File |
|
| March 29, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 18, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission F |
|
| March 19, 2013 |
Exhibit 2.1 TERMINATION AND TRANSITION AGREEMENT DATED AS OF MARCH 18, 2013 BY AND AMONG NPS PHARMACEUTICALS, INC., TAKEDA GmbH, AND TAKEDA PHARMA A/S TERMINATION AND TRANSITION AGREEMENT THIS TERMINATION AND TRANSITION AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2013 (the “Effective Date”), by and among NPS Pharmaceuticals, Inc., a Delaware corporation (“NPS”), Takeda Gm |
|
| March 19, 2013 |
Exhibit 99.1 For Immediate Release Contact: NPS Pharmaceuticals, Inc. Corporate Communications (908) 450-5516 [email protected] Takeda Pharmaceutical Company Limited Corporate Communications Dept. +81-3-3278-2037 Takeda Pharmaceuticals International GmbH +41445551501 [email protected] NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and |
|
| March 7, 2013 |
NPSP / NPS Pharmaceuticals Inc / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* NPS PHARMACEUTICALS, INC. (Name of Issuer) COMMON (Title of Class of Securities) 62936P103 (CUSIP Number) February 28, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule |
|
| February 21, 2013 |
Exhibit 99.1 NPS Pharmaceuticals Reports 2012 Financial Results and 2013 Guidance - Gattex® (teduglutide [rDNA Origin]) for injection now launched in the U.S. for the treatment of adult short bowel syndrome - - Conference call today at 4:30 PM ET - BEDMINSTER, N.J.-(BUSINESS WIRE)-February 21, 2013-NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering ther |
|
| February 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2013 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| February 14, 2013 |
EXHIBIT 99.1—JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 EXHIBIT 99.1—JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the co |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 14, 2013 |
NPSP / NPS Pharmaceuticals Inc / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* NPS PHARMACEUTICALS, INC. (Name of Issuer) COMMON (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed |
|
| February 13, 2013 |
Exhibit 10.4 NPS Pharmaceuticals Inc. Restricted Stock Unit Agreement Name: [[FIRSTNAME]] [[LASTNAME]] Award Number: [[GRANTNUMBER]] Grant Date: [[GRANTDATE]] Plan: [[STOCKOPTIONPLANNAME]] Award Type: [[GRANTTYPE]] Total Number of Units: [[SHARESGRANTED]] FMV on Date of Award: [[MARKETPRICEATAWARD]] THIS RESTRICTED STOCK UNIT AGREEMENT, is made and is effective as of the above Date of Grant betwee |
|
| February 13, 2013 |
Exhibit 10.3 NPS Pharmaceuticals Inc. Restricted Stock Unit Agreement Name: [[FIRSTNAME]] [[LASTNAME]] Award Number: [[GRANTNUMBER]] Grant Date: [[GRANTDATE]] Plan: [[STOCKOPTIONPLANNAME]] Award Type: [[GRANTTYPE]] Total Number of Units: [[SHARESGRANTED]] FMV on Date of Award: [[MARKETPRICEATAWARD]] THIS RESTRICTED STOCK UNIT AGREEMENT, is made and is effective as of the above Date of Grant betwee |
|
| February 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 12, 2013 NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of (Commission File No) (I.R |
|
| February 13, 2013 |
NPS Pharmaceuticals Inc. Stock Option Grant Agreement Exhibit-10.2 NPS Pharmaceuticals Inc. Stock Option Grant Agreement Optionee Name: [[FIRSTNAME]] [[LASTNAME]] Grant Number: [[GRANTNUMBER]] Date of Grant: [[GRANTDATE]] Plan: [[STOCKOPTIONPLANNAME]] Type: [[GRANTTYPE]] Total Number of Shares: [[SHARESGRANTED]] Exercise Price: [[GRANTPRICE]] Expiration Date: [[GRANTEXPIRATIONDATE]] THIS OPTION AGREEMENT is made and is effective as of the above Date |
|
| February 13, 2013 |
Exhibit 10.1 2005 Omnibus Incentive Plan NPS Pharmaceuticals, Inc. As amended through May 7, 2013 (subject to stockholder approval) Article 1. Establishment, Purpose, and Duration 1.1 Establishment. NPS Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to as the “Company”), establishes an incentive compensation plan to be known as the NPS Pharmaceuticals, Inc. 2005 Omnibus Incent |
|
| February 13, 2013 |
NPSP / NPS Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment npspharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: NPS Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 62936P103 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the approp |
|
| February 13, 2013 |
Exhibit 10.5 NPS Pharmaceuticals Inc. Restricted Stock Unit Agreement Name: [[FIRSTNAME]] [[LASTNAME]] Award Number: [[GRANTNUMBER]] Grant Date: [[GRANTDATE]] Plan: [[STOCKOPTIONPLANNAME]] Award Type: [[GRANTTYPE]] Total Number of Units: [[SHARESGRANTED]] FMV on Date of Award: [[MARKETPRICEATAWARD]] THIS RESTRICTED STOCK UNIT AGREEMENT, is made and is effective as of the above Date of Grant betwee |
|
| February 13, 2013 |
Exhibit 10.6 NPS Pharmaceuticals Inc. Restricted Stock Unit Agreement Name: [[FIRSTNAME]] [[LASTNAME]] Award Number: [[GRANTNUMBER]] Grant Date: [[GRANTDATE]] Plan: [[STOCKOPTIONPLANNAME]] Award Type: [[GRANTTYPE]] Total Number of Units: [[SHARESGRANTED]] FMV on Date of Award: [[MARKETPRICEATAWARD]] THIS RESTRICTED STOCK UNIT AGREEMENT, is made and is effective as of the above Date of Grant betwee |
|
| February 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) January 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 21, 2012 |
December 21, 2012 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission Washington, D.C. 20549 Attention: Mr. Jim B. Rosenberg, Senior Assistant Chief Accountant Re: NPS Pharmaceuticals, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended December 31, 2011 Filed February 15, 2012 Form 10-Q for the Quarterly Period Ended September 30, 2012 Filed November 9, 2012 Fil |
|
| December 12, 2012 |
AMENDED AND RESTATED NPS PHARMACEUTICALS, INC. ADOPTED BY THE BOARD OF DIRECTORS OCTOBER 31, 2012 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NPS PHARMACEUTICALS, INC. ADOPTED BY THE BOARD OF DIRECTORS ON OCTOBER 31, 2012 TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 CORPORATE SEAL 1 Section 2.1 Corporate Seal 1 ARTICLE 3 STOCKHOLDERS’ MEETINGS 1 Section 3.1 Place of Meetings 1 Section 3.2 Annual Meeting 1 Section 3.3 Special Me |
|
| December 12, 2012 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 12, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2012 |
Exhibit 99.1 NPS Pharmaceuticals Reports Third Quarter 2012 Financial Results and Reiterates Year-end Cash Guidance - FDA Advisory Committee unanimously recommends approval of Gattex® (teduglutide) for adult patients with short bowel syndrome - - One out of seven patients has now achieved independence from PN/IV fluids in ongoing STEPS 2 study - - Conference call today at 8:30 AM ET - BEDMINSTER, |
|
| November 9, 2012 |
Results of Operations and Financial Condition - NPS PHARMACEUTICALS, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission |
|
| August 1, 2012 |
Exhibit 99.1 NPS Pharmaceuticals Reports Second Quarter 2012 Financial Results - European CHMP recommends granting of marketing authorization for Revestive® (teduglutide) for adult patients with short bowel syndrome - - Amended Sensipar license agreement expected to provide at least $75 million of incremental cash through 2013 - - Company now expects to have sufficient capital to support the antic |
|
| August 1, 2012 |
Results of Operations and Financial Condition - NPS PHARMACEUTICALS, INC. 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission F |
|
| July 2, 2012 |
Exhibit 99.1 NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen Deal expected to accelerate at least $75 million for NPS by end of 2013 Proceeds to support anticipated product launches and financial independence BEDMINSTER, N.J.-(BUSINESS WIRE)-July 2, 2012-NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastroint |
|
| July 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 29, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 3, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commission File |
|
| May 3, 2012 |
Exhibit 99.1 NPS Pharmaceuticals Reports First Quarter 2012 Financial Results - Four additional patients weaned off parental nutrition and IV fluids while receiving Gattex therapy in ongoing STEPS 2 open-label extension study - - Results of Phase 3 REPLACE registration study of Natpara® accepted for oral presentation at the annual meeting of The Endocrine Society in June - - Conference call today |
|
| April 4, 2012 |
Use these links to rapidly review the document TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) February 29, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| February 29, 2012 |
NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors Exhibit 99.1 For Immediate Release Contact: Susan M. Mesco NPS Pharmaceuticals, Inc. (908)450-5516 [email protected] NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors BEDMINSTER, New Jersey — February 29, 2012 — NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announc |
|
| February 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 15, 2012 Date of Report (Date of earliest event reported) NPS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-23272 87-0439579 (State or other jurisdiction of incorporation) (Commissio |
|
| February 15, 2012 |
Exhibit 99.1 NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance - Recent highlights include positive results from Natpara™ Phase 3 registration study and acceptance of Gattex® NDA for adult short bowel syndrome - - Conference call today at 5:00 PM ET - BEDMINSTER, N.J.-(BUSINESS WIRE)-February 15, 2012-NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharm |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NPS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 10, 2012 |
EXHIBIT 99.1 - JOINT FILING AGREEMENT Joint Filing Agreement Exhibit 99.1 EXHIBIT 99.1 - JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is respo |
|
| February 10, 2012 |
Schedule 13G Amendment No. 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* NPS PHARMACEUTICALS, INC. (Name of Issuer) COMMON (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to |
|
| February 10, 2012 |
NPSP / NPS Pharmaceuticals Inc / Visium Asset Management, LP - AMENDMENT NO. 4 Passive Investment SC 13G/A 1 d299249dsc13ga.htm AMENDMENT NO. 4 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* NPS Pharmaceuticals (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 62936P103 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
